Laurus Labs has announced that it will host a conference call to discuss its Q4 and Full Year FY26 results on April 30, 2026, at 5:00 PM IST. The pharmaceutical company made this announcement on April 09, 2026, providing stakeholders with an opportunity to engage in an interactive discussion about the company's financial performance.

Conference Call Details

The earnings conference call will be hosted by DAM Capital Advisors and will feature a comprehensive discussion of the quarterly and annual results followed by an interactive Q&A session. The company has arranged multiple dial-in options to accommodate participants from various geographical locations:

Board Meeting and Financial Results

Prior to the conference call, the company's Board of Directors will meet on the same day to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The board will also deliberate on a second interim dividend payment for FY 2025-26 and fix the record date for shareholder eligibility.

Regulatory Compliance

The announcement was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also implemented a trading window closure for its directors and designated persons from April 01, 2026, to May 02, 2026, ensuring adherence to insider trading regulations.

Contact Information

For investor-related queries, stakeholders can reach out to Vivek Kumar at +91 40 3980 4366 or via email at investorrelations@lauruslabs.com . Media relations are handled by Karthik C, who can be contacted at +91 40 3980 4380 or mediarelations@lauruslabs.com .

The company secretary and compliance officer, G. Venkateswar Reddy, has signed the official communication to both BSE Limited (Code: 540222) and National Stock Exchange of India Ltd. (Code: LAURUSLABS), ensuring full transparency and regulatory compliance.

Laurus Labs Limited has received approval from unsecured creditors for its proposed Composite Scheme of Arrangement, marking a crucial step forward in the corporate restructuring process. The pharmaceutical company announced on April 07, 2026, that creditor meetings held the previous day resulted in unanimous support for the scheme.

Creditor Meeting Details

The meetings of unsecured creditors were conducted on April 06, 2026, in accordance with directions issued by the Hon'ble National Company Law Tribunal (NCLT), Amravati Special Branch. The company confirmed that both meetings achieved the requisite quorum and were conducted in a fair and transparent manner.

Scheme Structure and Participants

The Composite Scheme of Arrangement involves three key entities within the Laurus Labs group:

• Laurus Synthesis Private Limited - Demerged Company/Transferor Company (wholly-owned subsidiary)
• Sriam Labs Private Limited - Resulting Company (wholly-owned subsidiary)
• Laurus Labs Limited - Transferee Company (parent company)

The scheme is being implemented under Sections 230 to 232 of the Companies Act, 2013, along with the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016, and other applicable regulations.

Implementation Timeline and Next Steps

The creditor approval represents a significant milestone in the scheme's implementation process. However, the arrangement remains subject to several pending approvals:

• Approval from the Hon'ble National Company Law Tribunal
• Clearances from other statutory authorities
• Additional regulatory approvals as may be applicable

The company had previously communicated about the NCLT directions in its letter dated February 24, 2026, setting the stage for the April creditor meetings.

Regulatory Compliance

Laurus Labs filed this update under Regulation 30 of the listing regulations, ensuring transparency with stakeholders regarding this material corporate development. The company emphasized that all procedural requirements were met during the creditor meetings, maintaining compliance with legal and regulatory frameworks governing such arrangements.